Study details
Enrolling now
AMSC Trial for Anastomotic Stenosis
Houssam Farres, M.D.
NCT IDNCT04392206ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
15
Study length
about 7.1 years
Ages
18–85
Locations
1 site in FL
What this study is about
Researchers are testing the safety of using Adipose Derived Mesenchymal Stem Cells (AMSC) to improve access maturation and primary anastomotic patency in patients with Chronic Kidney Disease undergoing arteriovenous fistulas or arterial bypasses. The trial will last approximately 2602 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Adipose Derived Mesenchymal Stem Cells
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Number of participants with treatment-related adverse events
Body systems
Renal